We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer.
- Authors
Mitchell, Kyle G.; Amini, Behrang; Wang, Yunfei; Carter, Brett W.; Godoy, Myrna C. B.; Parra, Edwin R.; Behrens, Carmen; Villalobos, Pamela; Reuben, Alexandre; Lee, J. Jack; Weissferdt, Annikka; Moran, Cesar A.; Fujimoto, Junya; Sepesi, Boris; Walsh, Garrett L.; Vaporciyan, Ara A.; Hofstetter, Wayne L.; William, William N.; Gibbons, Don L.; Wang, Jing
- Abstract
Enhanced tumor glycolytic activity is a mechanism by which tumors induce an immunosuppressive environment to resist adoptive T cell therapy; therefore, methods of assessing intratumoral glycolytic activity are of considerable clinical interest. In this study, we characterized the relationships among tumor 18F-fluorodeoxyglucose (FDG) retention, tumor metabolic and immune phenotypes, and survival in patients with resected non-small cell lung cancer (NSCLC). We retrospectively analyzed tumor preoperative positron emission tomography (PET) 18F-FDG uptake in 59 resected NSCLCs and investigated correlations between PET parameters (SUVMax, SUVTotal, SUVMean, TLG), tumor expression of glycolysis- and immune-related genes, and tumor-associated immune cell densities that were quantified by immunohistochemistry. Tumor glycolysis-associated immune gene signatures were analyzed for associations with survival outcomes. We found that each 18F-FDG PET parameter was positively correlated with tumor expression of glycolysis-related genes. Elevated 18F-FDG SUVMax was more discriminatory of glycolysis-associated changes in tumor immune phenotypes than other 18F-FDG PET parameters. Increased SUVMax was associated with multiple immune factors characteristic of an immunosuppressive and poorly immune infiltrated tumor microenvironment, including elevated PD-L1 expression, reduced CD57+ cell density, and increased T cell exhaustion gene signature. Elevated SUVMax identified immune-related transcriptomic signatures that were associated with enhanced tumor glycolytic gene expression and poor clinical outcomes. Our results suggest that 18F-FDG SUVMax has potential value as a noninvasive, clinical indicator of tumor immunometabolic phenotypes in patients with resectable NSCLC and warrants investigation as a potential predictor of therapeutic response to immune-based treatment strategies.
- Subjects
POSITRON emission tomography; LUNG cancer; NON-small-cell lung carcinoma; TUMOR lysis syndrome
- Publication
Cancer Immunology, Immunotherapy, 2020, Vol 69, Issue 8, p1519
- ISSN
0340-7004
- Publication type
Article
- DOI
10.1007/s00262-020-02560-5